NCT04717375: An ongoing trial by Sanofi
This trial is ongoing. It must report results 6 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04717375 |
|---|---|
| Title | A Phase 1/2, Dose Escalation, Dose Expansion, and Dose Optimization Study of the Safety, Tolerability, and Anti-tumor Activity of SAR444881 Administered Alone and in Combination With Pembrolizumab, Cetuximab and/or Chemotherapy in Participants With Advanced Solid Tumors |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 11, 2021 |
| Completion date | July 2, 2025 |
| Required reporting date | July 2, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |